J. Westermarck

Transcriptional landscape of DTP-DTEP transition reveals DUSP6 as a driver of HER2 inhibitor tolerance via Neuregulin/HER3 axis

This study identifies DUSP6 as a driver of HER2 inhibitor tolerance through the Neuregulin/HER3 axis by analyzing the transcriptional changes during the DTP-DTEP transition in HER2+ breast cancer cells.

Pharmacological PP2A reactivation overcomes multikinase inhibitor tolerance across brain tumor cell models

This study identifies a triplet therapy combining AKT, PDK1-4 inhibition, and PP2A reactivation that effectively eradicates brain tumor models by overcoming kinase inhibitor tolerance through combinatorial effects on signaling rewiring, OXPHOS, and apoptosis.

RAS and PP2A activities converge on epigenetic gene regulation

This study identifies epigenetic gene regulation as a convergence point for RAS hyperactivity and PP2A inhibition in cancer, showing their co-regulation of key chromatin modifiers and oncogenic transcription.

PME-1 suppresses anoikis, and is associated with therapy relapse of PTEN-deficient prostate cancers

This study identifies PME-1 as a biomarker for aggressive PTEN-deficient prostate cancers by showing its role in suppressing anoikis.

SHARPIN serine 146 phosphorylation mediates ARP2/3 interaction, cancer cell invasion, and metastasis

This study identifies SHARPIN serine 146 phosphorylation as a key regulator of cancer cell invasion and metastasis by mediating ARP2/3 complex interaction and lamellopodia formation.

Development of Actionable Targets of Multi-kinase Inhibitors (AToMI) screening platform to dissect kinase targets of staurosporines in glioblastoma cells

The paper develops a platform to identify kinase targets of multi-kinase inhibitors in glioblastoma cells and finds AKT, PDK1, and PDK4 as targets of staurosporine derivatives that synergize with PP2A reactivation.

Ovarian cancers with low CIP2A tumor expression constitute an APR-246 sensitive disease subtype

The paper identifies ovarian cancers with low CIP2A expression as a subtype sensitive to APR-246, a ROS-inducing compound, and shows CIP2A's role in modulating NF-kB activity and drug response.

Circumventing drug treatment? Polyethylenimine functionalized nanoparticles inherently and selectively kill patient-derived glioblastoma stem cells

This study shows that PEI-functionalized nanoparticles selectively kill glioblastoma stem cells by lysosomal membrane rupture without affecting other cancer cells.

CIP2A interacts with TopBP1 and is selectively essential for DNA damage-induced basal-like breast cancer tumorigenesis

This study identifies CIP2A as a subtype-specific driver of DNA damage-induced basal-like breast cancer, showing its role in checkpoint signaling and therapeutic vulnerability.

Discovery of NOvel CIP2A VAriant (NOCIVA) and its clinical relevance in myeloid leukemias

The paper discovers a novel CIP2A splicing variant, NOCIVA, which is overexpressed in myeloid leukemias and correlates with poor clinical outcomes.

Monotherapy efficacy of BBB-permeable small molecule activators of PP2A in glioblastoma

This study shows that BBB-permeable PP2A activators reduce GB tumor growth and improve survival in mice with diverse GB subtypes.

ARPP19 promotes MYC expression and associates with patient relapse in acute myeloid leukemia

This study identifies ARPP19 as an oncogenic PP2A inhibitor in AML that predicts relapse independently of risk classification and is associated with disease activity.

Control of MYC-dependent apoptotic threshold by a co-amplified ubiquitin E3 ligase UBR5

This study identifies UBR5 as a novel MYC ubiquitin ligase that regulates MYC protein stability and apoptotic threshold in cancer cells and breast tissue.